DALLAS, May 1, 2012 (GLOBE NEWSWIRE) -- Miraca Life Sciences, Inc. ("MLS"), a specialist in the development and commercialization of the highest quality anatomic pathology services, today announced that Dr. Frank Basile will join the company as President and Chief Executive Officer. Dr. Basile brings more than 15 years of highly successful senior executive leadership experience in the healthcare and medical industry.

Most recently, Dr. Basile served as President and CEO of JDC Healthcare Management, a dental management company based in Dallas, Texas. While there, he was responsible for expanding the Company's business footprint and entering new markets, resulting in significant growth. Related executive experience includes serving as CEO and President of Diabetes America, an early stage company that operated first-ever health centers built expressly to fulfill the needs of diabetes patients.

"We are very pleased to welcome Dr. Basile to Miraca Life Sciences, our new group company, at this time," said Dr. Hiromasa Suzuki, President and CEO of Miraca Holdings, Inc. "Since MLS became a group company of Miraca Holdings in November 2011, we have formulated a new growth strategy and are confident that Dr. Basile's leadership and intimate knowledge and understanding of the business environment will enable MLS to achieve its strategic objectives."

In addition to his executive leadership experience, Dr. Basile previously worked at McKinsey & Company, a global management consulting firm, where he led extensive strategy, marketing and operations improvement projects for healthcare and biotechnology companies.

Dr. Basile is originally from Australia and received his Bachelor of Medicine, Bachelor of Surgery, MB, BS (MD equivalent) from the Faculty of Medicine at the University of Melbourne. He also graduated with distinction with a Master of Business Administration degree from the Melbourne Graduate School of Management, also at the University of Melbourne.

About Miraca Life Sciences

Miraca Life Sciences specializes in the development and commercialization of the highest quality anatomic pathology services, primarily in the fields of dermatopathology, hematopathology, gastrointestinal pathology and urologic pathology. The company's core team of more than 70 world-leading, academic-caliber specialists utilize state of the art pathology laboratories currently headquartered in Irving, TX and throughout the United States to serve more than 3,000 patients every day. Through rigorous quality assurance, daily and monthly conferences, and close relationships with clinical partners, Miraca Life Sciences continuously improves diagnostic precision.

About Miraca Holdings

With group net sales of JPY165.7 billion (FYE 3/2011), Miraca Holdings, a Japan-based holding company in the healthcare sector listed on the Tokyo Stock Exchange, is engaged in the business consisting of three segments: (i) development, manufacture, and commercialization of in vitro diagnostics, (ii) clinical laboratory testing, and (iii) other healthcare related businesses, which are conducted by its subsidiaries and affiliates including Fujirebio, Inc., a leading supplier of in vitro diagnostics in Japan, and SRL, Inc. ("SRL"), Japan's largest commercial laboratory. SRL offers comprehensive clinical laboratory testing services to medical institutes throughout the nation, ranging from general testing to esoteric testing, including gene-based tests.

See the original post here:
Dr. Frank Basile Joins Miraca Life Sciences as President and Chief Executive Officer